Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benchmarking antigen-aware inverse folding methods for antibody design.

Bioinformatics advances·2026
Same author

How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach.

Dermatology and therapy·2026
Same author

NAStructuralDB : structural database to facilitate computational studies of molecular modeling and recognition of proteins with special focus on antibody-antigen interactions.

mAbs·2026
Same author

ASD: antigen-specific antibody database.

mAbs·2026
Same author

AbDesign: database of point mutants of antibodies with associated structures reveals poor generalization of binding predictions from machine learning models.

mAbs·2025
Same author

Conserved heavy/light contacts and germline preferences revealed by a large-scale analysis of natively paired human antibody sequences and structural data.

Communications biology·2025
Same journal

Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic.

mAbs·2026
Same journal

Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning.

mAbs·2026
Same journal

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle<sup>TM</sup> variants.

mAbs·2026
Same journal

Development of single-chain C1q affinity chromatography-mass spectrometry for the glycoform-resolved characterization of low-affinity immunoglobulin G interactions.

mAbs·2026
Same journal

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency.

mAbs·2026
Same journal

Comparison of knockdown approaches for the generation of stable cell populations expressing afucosylated antibodies.

mAbs·2026
See all related articles

Related Experiment Video

Updated: Nov 12, 2025

Semi-automated Biopanning of Bacterial Display Libraries for Peptide Affinity Reagent Discovery and Analysis of Resulting Isolates
13:49

Semi-automated Biopanning of Bacterial Display Libraries for Peptide Affinity Reagent Discovery and Analysis of Resulting Isolates

Published on: December 6, 2017

11.7K

Data mining patented antibody sequences.

Konrad Krawczyk1, Andrew Buchanan2, Paolo Marcatili3

  • 1Research and Development, Natural Antibody, Hamburg, Germany.

Mabs
|March 16, 2021
PubMed
Summary
This summary is machine-generated.

Patent literature contains valuable antibody sequence data for therapeutic antibody engineering. Analysis shows these sequences accurately reflect clinical antibodies, suggesting patents can guide future rational antibody design.

Keywords:
Patentsdata miningtherapeutic Antibodies

More Related Videos

Analysis of Histone Antibody Specificity with Peptide Microarrays
09:47

Analysis of Histone Antibody Specificity with Peptide Microarrays

Published on: August 1, 2017

41.2K
Identification of Mouse and Human Antibody Repertoires by Next-Generation Sequencing
08:51

Identification of Mouse and Human Antibody Repertoires by Next-Generation Sequencing

Published on: March 15, 2019

12.7K

Related Experiment Videos

Last Updated: Nov 12, 2025

Semi-automated Biopanning of Bacterial Display Libraries for Peptide Affinity Reagent Discovery and Analysis of Resulting Isolates
13:49

Semi-automated Biopanning of Bacterial Display Libraries for Peptide Affinity Reagent Discovery and Analysis of Resulting Isolates

Published on: December 6, 2017

11.7K
Analysis of Histone Antibody Specificity with Peptide Microarrays
09:47

Analysis of Histone Antibody Specificity with Peptide Microarrays

Published on: August 1, 2017

41.2K
Identification of Mouse and Human Antibody Repertoires by Next-Generation Sequencing
08:51

Identification of Mouse and Human Antibody Repertoires by Next-Generation Sequencing

Published on: March 15, 2019

12.7K

Area of Science:

  • Biotechnology
  • Intellectual Property Law
  • Bioinformatics

Background:

  • Patent literature represents decades of antibody engineering efforts.
  • Patents primarily offer legal protection, raising questions about their utility for scientific knowledge transfer.
  • Assessing the value of antibody sequences in patents for therapeutic antibody design is crucial.

Purpose of the Study:

  • To quantify antibody sequences in patents for medicinal purposes.
  • To evaluate how well these patent sequences represent therapeutic antibodies in clinical use.
  • To determine the utility of patent data for rational antibody design.

Main Methods:

  • Identified 16,526 patent families from major jurisdictions (USPTO, WIPO).
  • Compiled 245,109 unique antibody chains (heavy and light) into the Patented Antibody Database (PAD).
  • Analyzed the proportion of antibody sequences in patent databases and their correlation with clinical antibody sequences.

Main Results:

  • Antibody sequences constitute a significant portion (11%) of patent sequence data.
  • The number of patent documents containing antibody sequences is increasing, predominantly for medicinal applications.
  • Sequences from patent literature closely mirror those of clinically used antibody therapeutics.

Conclusions:

  • Patent literature is a rich, growing source of antibody sequence information.
  • Patent data accurately reflects therapeutic antibody sequences, validating its use for engineering.
  • The patent landscape can serve as a valuable reference for advancing rational antibody design.